Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1979 1
1980 1
1985 1
1988 1
1989 3
1991 2
1992 1
1994 2
1995 4
1996 8
1997 5
1998 5
1999 5
2000 4
2001 4
2002 9
2003 6
2004 9
2005 8
2006 8
2007 56
2008 147
2009 227
2010 393
2011 577
2012 768
2013 906
2014 1208
2015 1449
2016 1570
2017 1892
2018 2144
2019 2358
2020 2925
2021 3312
2022 3375
2023 3403
2024 1150

Text availability

Article attribute

Article type

Publication date

Search Results

24,940 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenesis of Triple-Negative Breast Cancer.
Derakhshan F, Reis-Filho JS. Derakhshan F, et al. Annu Rev Pathol. 2022 Jan 24;17:181-204. doi: 10.1146/annurev-pathol-042420-093238. Annu Rev Pathol. 2022. PMID: 35073169 Free PMC article. Review.
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with different histologic, genomic, and immunologic profiles, which are aggregated under this term because of their lack of estrogen receptor, pr …
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with …
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM. Yang F, et al. Cell Metab. 2023 Jan 3;35(1):84-100.e8. doi: 10.1016/j.cmet.2022.09.021. Epub 2022 Oct 17. Cell Metab. 2023. PMID: 36257316 Free article.
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. ...
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metaboli …
Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L, Duan JJ, Bian XW, Yu SC. Yin L, et al. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. Breast Cancer Res. 2020. PMID: 32517735 Free PMC article. Review.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include hi …
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express es …
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Li Y, et al. J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. J Hematol Oncol. 2022. PMID: 36038913 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients ha …
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a po …
Epidemiology of Triple-Negative Breast Cancer: A Review.
Howard FM, Olopade OI. Howard FM, et al. Cancer J. 2021 Jan-Feb 01;27(1):8-16. doi: 10.1097/PPO.0000000000000500. Cancer J. 2021. PMID: 33475288 Review.
Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor-positive disease. ...Even controlling for treatment delays, stage, a …
Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United States from 201 …
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has sever …
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy o …
Pathology of triple negative breast cancer.
Borri F, Granaglia A. Borri F, et al. Semin Cancer Biol. 2021 Jul;72:136-145. doi: 10.1016/j.semcancer.2020.06.005. Epub 2020 Jun 13. Semin Cancer Biol. 2021. PMID: 32544511 Review.
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24 % of newly diagnosed breast neoplasms. In this review, pathological aspects of …
Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression an …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that a …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong CW, Tan D, Liu Q, Xie X. Zou Y, et al. Int J Surg. 2022 Nov;107:106936. doi: 10.1016/j.ijsu.2022.106936. Epub 2022 Sep 20. Int J Surg. 2022. PMID: 36341760
BACKGROUND: Postoperative progression and chemotherapy resistance is the major cause of treatment failure in patients with triple-negative breast cancer (TNBC). Currently, there is a lack of an ideal predictive model for the progression and drug sensit …
BACKGROUND: Postoperative progression and chemotherapy resistance is the major cause of treatment failure in patients with triple- …
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Bianchini G, De Angelis C, Licata L, Gianni L. Bianchini G, et al. Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. doi: 10.1038/s41571-021-00565-2. Epub 2021 Nov 9. Nat Rev Clin Oncol. 2022. PMID: 34754128 Review.
Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least favourable outcomes. In the past few years, advances in omics tech …
Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negativ …
24,940 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "triple negative breast cancer"